Peter J. Houghton

40.0k citations

571 papers · 28.8k indexed · 3 hit papers · h-index 86

Oncology top 0.1%
- CAR-T cell therapy research 31
- Lung Cancer Research Studies 29
Molecular Biology top 0.1%
- Cancer therapeutics and mechanisms 95
- PI3K/AKT/mTOR signaling in cancer 60
Complementary and alternative medicine top 0.05%
Cancer Research top 0.2%
- Cancer, Hypoxia, and Metabolism 36
Pharmacology top 0.05%
Neurology
- Neuroblastoma Research and Treatments 95
Pulmonary and Respiratory Medicine
- Sarcoma Diagnosis and Treatment 61
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 30

Co-authors: Mary‐Ann Bjornsti Janet A. Houghton Christopher L. Morton John Easton Shile Huang Malcolm A. Smith Raushan T. Kurmasheva Pulok K. Mukherjee
Cited by: Oncology Molecular Biology Complementary and alternative medicine
Journals: Nature (1 paper)Science (1 paper)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Peter J. Houghton

561 papers receiving 27.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Peter J. Houghton

Since Specialization

Citations

This map shows the geographic impact of Peter J. Houghton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Houghton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Houghton more than expected).

Fields of papers citing papers by Peter J. Houghton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Houghton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Houghton. The network helps show where Peter J. Houghton may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter J. Houghton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter J. Houghton Line = papers co-authored together Peter J. Houghton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma Molecular Cancer Therapeutics ·Nicole R. Hensch,Kathryn Bondra,Long Wang,Prethish Sreenivas,Xiang R. Zhao,Paulomi Modi,Angelina V. Vaseva,Peter J. Houghton,Myron S. Ignatius	2022	0
2	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models Cancer Research ·Shaun D. Fontaine,Gary W. Ashley,Peter J. Houghton,Raushan T. Kurmasheva,Morgan E. Diolaiti,Alan Ashworth,Cody J. Peer,Ryan Nguyen,William D. Figg,Denis Beckford-Vera,Daniel V. Santi	2020	16
3	Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts Clinical Cancer Research ·Andrew J. Robles,Raushan T. Kurmasheva,Abhik Bandyopadhyay,Doris A. Phelps,Stephen W. Erickson,Zhao Lai,Dias Kurmashev,Yidong Chen,Malcolm A. Smith,Peter J. Houghton	2020	11
4	Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling Clinical Cancer Research ·Michele Dowless,Caitlin D. Lowery,Terry J. Shackleford,Matthew Renschler,Jennifer Stephens,Robert S. Flack,Wayne Blosser,Simone Gupta,Julie Stewart,Yue Webster,Jack Dempsey,Alle B. VanWye,Philip J. Ebert,Philip W. Iversen,Jonathan B. Olsen,Xueqian Gong,Sean G. Buchanan,Peter J. Houghton,Louis F. Stancato	2018	47
5	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL Clinical Cancer Research ·Luke Jones,Jennifer Richmond,Kathryn Evans,Hernán Carol,Duohui Jing,Raushan T. Kurmasheva,Catherine A. Billups,Peter J. Houghton,Malcolm A. Smith,Richard B. Lock	2017	17
6	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant Cancer Research ·Jennifer Richmond,Alissa K. Robbins,Kathryn Evans,Dominik Beck,Raushan T. Kurmasheva,Catherine A. Billups,Hernán Carol,Susan L. Heatley,Rosemary Sutton,Glenn M. Marshall,Deborah L. White,John E. Pimanda,Peter J. Houghton,Malcolm A. Smith,Richard B. Lock	2016	18
7	The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma Molecular Cancer Therapeutics ·Hemant K. Bid,Doris A. Phelps,Linlin Xaio,Denis C. Guttridge,Jiayuh Lin,Cheryl A. London,Laurence H. Baker,Xiaokui Mo,Peter J. Houghton	2016	66
8	Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic Leukemia Clinical Cancer Research ·Jennifer Richmond,Hernán Carol,Kathryn Evans,Laura High,Agnes Mendomo,Alissa K. Robbins,Claus Meyer,Nicola C. Venn,Rolf Marschalek,Michelle J. Henderson,Rosemary Sutton,Raushan T. Kurmasheva,Ursula R. Kees,Peter J. Houghton,Malcolm A. Smith,Richard B. Lock	2015	41
9	HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer Cancer Research ·Kellie S. Rath,Shan K. Naidu,Pushpa Lata,Hemant K. Bid,Brian K. Rivera,Georgia A. McCann,Brent J. Tierney,Adam C. ElNaggar,Veronica Bravo,Gustavo Leone,Peter J. Houghton,Kálmán Hideg,Periannan Kuppusamy,David E. Cohn,Karuppaiyah Selvendiran	2014	76
10	FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene Clinical Cancer Research ·Mamata Singh,Justin M. Leasure,Christopher Chronowski,Brian Geier,Kathryn Bondra,Wenrui Duan,Lauren A. Hensley,Miguel A. Villalona‐Calero,Ning Li,Anthony M. Vergis,Raushan T. Kurmasheva,Changxian Shen,Gary Woods,Nikhil Sebastian,Denise Fabian,Rita Kaplon,Sue Hammond,Kamalakannan Palanichamy,Arnab Chakravarti,Peter J. Houghton	2014	11
11	Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks Cancer Research ·Changxian Shen,Duane Oswald,Doris A. Phelps,Hakan Çam,Christopher E. Pelloski,Qishen Pang,Peter J. Houghton	2013	74
12	Bioactive Lipids S1P and C1P Are Prometastatic Factors in Human Rhabdomyosarcoma, and Their Tissue Levels Increase in Response to Radio/Chemotherapy Molecular Cancer Research ·Gabriela Schneider,Ewa Bryndza,Ahmed Abdel‐Latif,Janina Ratajczak,Magdalena Maj,Maciej Tarnowski,Yuri M. Klyachkin,Peter J. Houghton,Andrew J. Morris,Axel Vater,Sven Klußmann,Magda Kucia,Mariusz Z. Ratajczak	2013	61
13	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma Clinical Cancer Research ·Hemant K. Bid,Aaron Kibler,Doris A. Phelps,Sagymbek Manap,Linlin Xiao,Jiayuh Lin,David Capper,Duane Oswald,Brian Geier,Mariko DeWire,Paul D. Smith,Raushan T. Kurmasheva,Xiaokui Mo,Soledad Fernández,Peter J. Houghton	2013	49
14	ΔNp63 Promotes Pediatric Neuroblastoma and Osteosarcoma by Regulating Tumor Angiogenesis Cancer Research ·Hemant K. Bid,Ryan D. Roberts,Maren Cam,Anthony Audino,Raushan T. Kurmasheva,Jiayuh Lin,Peter J. Houghton,Hakan Çam	2013	47
15	Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy Clinical Cancer Research ·Hemant K. Bid,Cheryl A. London,Jin Gao,Haihong Zhong,Robert E. Hollingsworth,Soledad Fernández,Xiaokui Mo,Peter J. Houghton	2013	18
16	The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia Clinical Cancer Research ·Hernán Carol,Barbara Szymanska,Kathryn Evans,Ingrid Boehm,Peter J. Houghton,Malcolm A. Smith,Richard B. Lock	2013	57
17	Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin Molecular Cancer Therapeutics ·Shripad V. Bhagwat,Prafulla C. Gokhale,Andrew P. Crew,Andy Cooke,Yan Yao,Christine Mantis,Jennifer Kahler,Jennifer E. Workman,Mark Bittner,Lorina Dudkin,David Epstein,Neil W. Gibson,Robert Wild,Lee D. Arnold,Peter J. Houghton,Jonathan A. Pachter	2011	159
18	Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507 Clinical Cancer Research ·Emmy D.G. Fleuren,Yvonne M.H. Versleijen‐Jonkers,Addy C.M. van de Luijtgaarden,Janneke D.M. Molkenboer‐Kuenen,Sandra Heskamp,Melissa H.S. Roeffen,Hanneke W.M. van Laarhoven,Peter J. Houghton,Wim J.G. Oyen,Otto C. Boerman,Winette T.A. van der Graaf	2011	37
19	Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2 Molecular Cancer Therapeutics ·Hemant K. Bid,Jun Zhan,Doris A. Phelps,Raushan T. Kurmasheva,Peter J. Houghton	2011	57
20	Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors Journal of Clinical Oncology ·Wayne L. Furman,Fariba Navid,Najat C. Daw,M. Beth McCarville,Lisa M. McGregor,Sheri L. Spunt,Carlos Rodríguez‐Galindo,John C. Panetta,Kristine R. Crews,Jianrong Wu,Amar Gajjar,Peter J. Houghton,Victor M. Santana,Clinton F. Stewart	2009	42

About Peter J. Houghton

Peter J. Houghton is a scholar working on Oncology, Neurology and Molecular Biology, having authored 571 papers that have together received 28.8k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (95 papers), Cancer therapeutics and mechanisms (95 papers), Sarcoma Diagnosis and Treatment (61 papers), PI3K/AKT/mTOR signaling in cancer (60 papers), Cancer, Hypoxia, and Metabolism (36 papers), CAR-T cell therapy research (31 papers), Acute Lymphoblastic Leukemia research (30 papers) and Lung Cancer Research Studies (29 papers). The work is most often cited by research in Oncology (7.5k citations), Molecular Biology (15.6k citations) and Complementary and alternative medicine (1.8k citations). Peter J. Houghton has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Mary‐Ann Bjornsti, Janet A. Houghton, Christopher L. Morton, John Easton, Shile Huang, Malcolm A. Smith, Raushan T. Kurmasheva, Pulok K. Mukherjee, Kumar Venkatesan and Clinton F. Stewart. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact